GENE ONLINE|News &
Opinion
Blog

2022-11-15| Trials & Approvals

Roche’s Gantenerumab Fails Trials In Alzheimer’s Disease

by Joy Lin
Share To

Roche’s candidate for Alzheimer’s disease, gantenerumab, failed to slow disease progression in people in the early stages of the disease, leaving rivals Biogen and Eisai as the leaders in the field.

News of the flop caused shares in Roche to drop 3.4%, their lowest point in almost seven weeks. Meanwhile, shares in their development partner Morphosys were down 29%. 

“So many of our families have been directly affected by Alzheimer’s, so this news is very disappointing to deliver,” said Levi Garraway, MD, Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development.

“We are profoundly grateful to the study participants, their care partners, and study sites for their contributions to this research. While the Graduate results are not what we hoped, we are proud to have delivered a high-quality, clear and comprehensive Alzheimer’s dataset to the field, and we look forward to sharing our learnings with the community as we continue to search for new treatments for this complex disease.”

Related Article: Roche Bags Fast Track Label for New Alzheimer’s Diagnostic

Failing Primary Endpoints 

In a statement, the Swiss company said that while the Graduate 1 and 2 studies on gantenerumab showed some benefit in slowing clinical decline, the results were not statistically significant. 

The level of beta-amyloid, a protein that accumulates and forms plaques in the brains of Alzheimer’s patients, was lower than expected, Roche said. The company will present more detailed data at the Clinical Trials on Alzheimer’s Disease conference in San Francisco on November 30. 

Roche’s setback leaves rivals Biogen and Eisai at the forefront of the race to develop an Alzheimer’s treatment. In September, Biogen and Eisai reported a trial success with lecanemab, which met the primary endpoint and all secondary endpoints. 

Topline results from the Phase 3 Clarity AD clinical trial revealed that lecanamab reduced cognitive and functional decline by 27% at 18 months versus placebo. 

Lecanemab targets the earlier stages of amyloid buildup, compared to Roche’s drug which targets larger amyloid structures. The news of Roche’s failure has bolstered confidence in lecanemab, sending shares in Biogen up 3.8%. 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Eisai and Biogen’s Alzheimer’s Med, Leqembi, Granted FDA Approval
2023-01-09
Belharra Therapeutics Exits Stealth With $130 Million And A Genentech Deal
2023-01-05
Roche’s Lunsumio Lands FDA Approval for Pretreated Follicular Lymphoma
2022-12-26
LATEST
Junshi’s PD-1 Antibody Meets Endpoint In Phase 3 Lung Cancer Trial
2023-01-19
Moderna Welcomes Phase 3 Win For RSV Vaccine
2023-01-18
Moving Beyond COVID With mRNA Technology
2023-01-18
Rob Knight and Jing-Yuan Fu Elaborate On Microbiome Research Trends at the 7th Asia Microbiome Conference(AMC)
2023-01-17
CARsgen Taps Huadong to Commercialize Multiple Myeloma CAR-T in China
2023-01-17
Scientists Study Imaging Probes in First-Ever Amputated Human Limb Model
2023-01-16
EMA Plans to Issue Liver Failure Warning for Novartis’ Gene Therapy
2023-01-16
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!